AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Oct 29, 2026 Ligand reported third-quarter 2026 royalty revenue up 51% year-over-year to $70.3 million and raised its full-year 2026 adjusted diluted EPS guidance to $9.50 to $9.75. AI-generated summary · Source: company release
Nasdaq: $LGNDBiotech · Royalty investmentsPartner execution, financing and royalty accounting

LGND Stock Hub: Ligand Pharmaceuticals News, Royalties and Partner Catalysts

Q3 royalties were $70.284M, with $78.746M total revenues and income and a $28.485M GAAP net loss. Cash and short-term investments were $447.395M at September 30, alongside $1.16B convertible principal. Investor Day is announced for December 8; QTORIN already has an accepted NDA and February 2027 FDA target. Q3 2026 Form 10-Q · October 30 Investor Day schedule · announced October 22 QTORIN NDA acceptance and Priority Review · October 28, 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: September 30, 2026Currency: USD
Research Library · Biotech
Ligand Pharmaceuticals: Royalty Growth, XOMA and Partner Catalysts
Commercial economics, partner trials, cash conversion and capital structure · November 12, 2026
Get the report (PDF)
Next catalyst · Announced company investor event
December 8, 2026 · Investor Day, 10:30–12:00 New York

Ligand plans presentations on strategy, investments, the royalty portfolio and long-term financial outlook, with Palvella CEO Wes Kaupinen as a guest speaker. The five-year outlook update remains a company plan. Investor Day schedule · announced October 22 Q3 results and guidance · October 29, 2026

The November 9 and 10 Ligand conference dates have passed. Orchestra announced a November 12 R&D Day at 15:00 New York; its November 10 release describes BACKBEAT enrollment completion, with primary data intended for HRS 2027. November conferences · announced October 27 Orchestra BACKBEAT and regulatory update · November 10, 2026
LGND daily price chart
Daily chart · Finviz (affiliate link on click). Explore LGND on JC Just Charts.

LGND stock data: financial position and capital

Regular close
$316.83
November 11, 2026 · completed regular session
Common-stock value
$6.338B
Calculated: 20,002,986 shares · October 27
Q3 royalties
$70.284M
$47.427M intangible revenue + $22.857M financial income
Q3 total revenues and income
$78.746M
Quarter ended September 30, 2026
Cash and short-term investments
$447.395M
September 30 · restricted cash excluded
2026 royalty guidance
$225–250M
Company forecast · October 29
2026 adjusted diluted EPS
$9.50–9.75
Non-GAAP company guidance · raised October 29
Convertible principal
$1.160B
$460M due 2030 + $700M due 2031

Deployable capital of approximately $750M also counts equity holdings and credit availability; it is not additional cash. Financial royalty income and cash receipts differ. Both note principals require cash settlement upon conversion. Q3 2026 Form 10-Q · October 30 Q3 results and guidance · October 29, 2026

Royalty aggregation broadens the portfolio and the financial claims

Commercial royalties and development milestones depend on partners. Accepted applications and completed enrollment remain separate from approval and successful readouts; financial royalty income is not identical to cash received. Q3 2026 Form 10-Q · October 30 QTORIN NDA acceptance and Priority Review · October 28, 2026 Orchestra BACKBEAT and regulatory update · November 10, 2026

▲ The constructive case

Filspari growth and the completed XOMA acquisition expanded the royalty base. Multiple marketed assets and partner trials spread exposure across diseases, with an Investor Day outlook update and several clinical or regulatory windows. Q3 2026 Form 10-Q · October 30 Investor Day schedule · announced October 22 Q3 presentation · October 29, 2026

▼ The cautious case

A larger asset count does not eliminate concentration, partner execution or integration risk. Q3 GAAP loss and negative quarterly operating cash flow contrast with positive adjusted earnings; convertible settlement and new investment commitments affect available capital. Q3 2026 Form 10-Q · October 30 Q3 results and guidance · October 29, 2026

Latest LGND news

Oct 29, 2026

Ligand reports third quarter 2026 financial results; royalty revenue up 51% to $70.3 million

Third-quarter 2026 royalty revenue increased 51% year-over-year to $70.3 million, compared with $46.6 million for the prior-year period. Total revenues and income were $78.7 million, compared with $115.5 million, a decrease of 32% that reflects prior-year Pelthos divestiture-related income of $53.1 million. Full-year 2026 adjusted diluted EPS guidance was raised to $9.50 to $9.75, from $9.00 to $9.50. GAAP net loss was $28.5 million, or $1.43 per share, for the quarter.

Company release · SEC

LGND stock catalysts: Investor Day and partner development windows

QTORIN submission is complete and accepted, superseding an old H2 2026 filing target. Dates such as December 31 marking broad windows are not exact company-announced event days. Registry completion estimates are distinct from disclosure plans. QTORIN NDA acceptance and Priority Review · October 28, 2026 Q3 results and guidance · October 29, 2026

Ligand royalties: FILSPARI, OHTUVAYRE and XOMA

Q3 FILSPARI royalty revenue was $16.839M. OHTUVAYRE contributed $3.704M in intangible royalty revenue and $3.251M in financial royalty income, with different accounting. XOMA brought OJEMDA, VABYSMO and MIPLYFFA interests into the portfolio after the July 14 closing. Q3 2026 Form 10-Q · October 30 Current royalty portfolio and economic interests · November 12, 2026 XOMA acquisition completed · July 14, 2026

LGND earnings and the financing structure

2026 revenue guidance remains $270–310M; adjusted diluted EPS guidance rose to $9.50–9.75. Q3 adjusted net income was $57.5M versus a $28.485M GAAP loss. The convertible principals require cash settlement; hedges, warrants and employee awards have separate dilution effects. Q3 results and guidance · October 29, 2026 Q3 2026 Form 10-Q · October 30

Merlintrader Health Score · LGND

3.70out of 5
Financial position3.5

September cash and short-term investments were $447.395M, with $1.16B convertible principal and $124.4M available on the revolver. Nine-month operating cash flow was $45.118M. Q3 2026 Form 10-Q · October 30

Catalysts4.0

Investor Day is announced for December 8; partner windows include mid-December upLIFT, February 28 QTORIN and Q1 VANTAGE. These remain different event types. Investor Day schedule · announced October 22 Rezolute quarterly and clinical update · November 5, 2026 QTORIN NDA acceptance and Priority Review · October 28, 2026 Mirum Q3 and volixibat timing · November 3, 2026

Dilution3.0

September options numbered 2,073,834 and restricted awards 433,699. Notes require cash principal settlement, while conversion spreads, warrants and the unused ATM create separate potential equity claims. Q3 2026 Form 10-Q · October 30

Trading liquidity4.0

LGND trades on Nasdaq; October 27 common shares totaled 20,002,986. The share count is not the public float, and partner events can cause price gaps. Q3 2026 Form 10-Q · October 30

Execution4.5

Q3 royalties reached $70.284M, XOMA closed July 14, and current adjusted EPS guidance increased. Commercial growth coexists with GAAP and cash-flow volatility. Q3 2026 Form 10-Q · October 30 Q3 results and guidance · October 29, 2026 XOMA acquisition completed · July 14, 2026

Weighted calculation: 3.5 × 30% + 4.0 × 30% + 3.0 × 20% + 4.0 × 10% + 4.5 × 10% = 3.70 out of 5. Editorial assessment dated November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of approval.

LGND red flags

LGND Stock FAQ: Ligand Pharmaceuticals Questions Answered

What is the next LGND stock catalyst for Ligand Pharmaceuticals?

As of November 12, 2026, Ligand Investor Day was announced for December 8, 10:30–12:00 New York, covering strategy, investments and long-term financial outlook. Partner Rezolute targets upLIFT topline results in mid-December; the events have different purposes and uncertainty. Investor Day schedule · announced October 22 Rezolute quarterly and clinical update · November 5, 2026

Is the LGND partner QTORIN rapamycin approved?

On October 28, 2026, Palvella announced FDA acceptance and Priority Review of the QTORIN rapamycin NDA for microcystic lymphatic malformations, with a February 28, 2027 target action date. The candidate remains investigational; acceptance and Priority Review do not establish approval. QTORIN NDA acceptance and Priority Review · October 28, 2026

How much cash does Ligand Pharmaceuticals have for LGND operations?

At September 30, 2026, cash and equivalents of $55.958M plus short-term investments of $391.437M totaled $447.395M, excluding $47.433M restricted cash. The approximately $750M deployable-capital figure also includes equity holdings and credit availability. Convertible principal remains a separate obligation. Q3 2026 Form 10-Q · October 30 Q3 results and guidance · October 29, 2026

What are LGND share dilution risks?

At September 30, 2026, Ligand had 2,073,834 options and 433,699 restricted awards, alongside warrants and two convertible-note series. Note principal must be settled in cash on conversion; the conversion spread can be settled in cash, shares or both. Contractual share equivalents differ from actual dilution. Q3 2026 Form 10-Q · October 30

What were the latest LGND earnings from Ligand Pharmaceuticals?

For Q3 ended September 30, 2026, total revenues and income were $78.746M, including $70.284M royalties. GAAP net loss was $28.485M, while adjusted net income was $57.5M and adjusted diluted EPS $2.67. The adjusted figures are non-GAAP measures. Q3 2026 Form 10-Q · October 30 Q3 results and guidance · October 29, 2026

What does Ligand Pharmaceuticals do for LGND holders?

As of November 12, 2026, Ligand aggregates drug royalties, finances partner programs and licenses technologies including Captisol. Its economic interests span marketed and investigational assets; partner sales, royalty income, milestones and Captisol material sales represent different revenue streams. Q3 2026 Form 10-Q · October 30 Current royalty portfolio and economic interests · November 12, 2026

Did LGND complete the XOMA acquisition?

On July 14, 2026, Ligand completed its acquisition of XOMA Royalty. The transaction added commercial and development-stage economic interests, including OJEMDA, VABYSMO and MIPLYFFA. Closing is complete, while integration, future partner sales and clinical outcomes remain ongoing execution questions. XOMA acquisition completed · July 14, 2026 Q3 2026 Form 10-Q · October 30

Why does LGND report two OHTUVAYRE royalty amounts?

For Q3 ended September 30, 2026, OHTUVAYRE contributed $3.704M as intangible royalty revenue and $3.251M as financial royalty income from the inventor interest. Ligand lists a combined 3% economic royalty interest, but the two accounting streams do not equal a simple current-quarter cash collection. Q3 2026 Form 10-Q · October 30 Current royalty portfolio and economic interests · November 12, 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $LGND or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics
LNG carrier, onshore facility and floating liquefaction vessel in a sunlit coastal scene.
Cheniere $LNG $VG $NEXT $GLNG: Four LNG Business Models